Upon completion of this educational activity, participants will be better able to:
Links: English Program French Program
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by The Canadian Cardiovascular Society and The Canadian Society of Nephrology. You may claim a maximum of 1.5 hours (Credits will be updated accordingly in MAINPORT). ID# 00013621
This learning program is brought to you by the CPD Network, a not-for-profit physician organization.
Internationally renowned expert, Dr. Daniel Bichet answers your questions on ADPKD - its pathophysiology, workup and management. Dr. Daniel Bichet is the Director of the Clinical Research Unit at l'Hôpital Sacré-Coeur in Montreal. He is also a Professor of Medicine at l'Université de Montréal.
Since 1987 Dr. Bichet has been studying nephrogenic diabetes insipidus at l'Hôpital du Sacré Coeur in Montreal. This hereditary kidney disorder appears at birth and causes episodes of severe dehydration in newborns. Late diagnosis or lack of treatment can result in kidney failure. Through research funded by The Kidney Foundation, Dr. Bichet and his research team have identified the gene that causes this type of diabetes and they have developed a blood test to detect it. More recently, he has applied some of the knowledge gained in the study of nephrogenic diabetes insipidus to a new study on polycystic kidney disease, a more common hereditary condition. For his work, Dr. Bichet recently was awarded The Kidney Foundation's Medal for Research Excellence, which is presented annually to a Canadian resident who is recognized nationally and internationally for excellence in kidney-related research.
Recent ADPKD Questions:
This channel was made possible with the support of Otsuka Canada Pharmaceutical Inc. (“Sponsor”). The views expressed in this channel do not necessarily reflect those of UKidney and the Sponsor. This channel might include information about drugs or indications that have not been approved in Canada.